InvestorsHub Logo
Followers 12
Posts 1102
Boards Moderated 0
Alias Born 01/27/2017

Re: tsand post# 171562

Saturday, 11/23/2019 3:43:16 PM

Saturday, November 23, 2019 3:43:16 PM

Post# of 203912
The company's main preoccupation at this point is to keep the wolves at bay and keeping the doors open. Looking at the 10-K for ongoing studies won't do you much good, as that is in the past. The most recent !0-Q that came out on November 13 makes a brief mention of the tablet study conducted earlier in the year. Found towards the end of page 30 and the first 4 paragraphs on page 31.

Our TLR conclusions were that MGC-ODT has a tolerable safety profile and appeared to have similar PK and bioavailability as Sativex®. Based on such top line data, OWC intends to apply to the Israel Ministry of Health to obtain necessary approvals to market its Medical Grade Cannabis - Orally Disintegrating Tablets in Israel.


So the question should be has OWC made the application, or do they just "intend" to apply? They desperately need money so I would think the quicker they get the approvals the better. Would be nice to know!

The only reference to the psoriasis study is found at the top of page 33.

On June 28, 2018, we announced the successful completion of the first part of our Phase I, placebo controlled, maximal dose trial (the “Psoriasis Trial”) to determine the safety and tolerability of the topical ointment containing medical grade cannabis (the “Topical Ointment”) in healthy volunteers. The completed part of our Psoriasis Trial consisted of application of escalating doses of the Topical Ointment to healthy volunteers and was successfully completed with no adverse effects. On January 29, 2019 we reported positive Phase 1 safety data for our medical grade cannabis MGC ointment for the treatment of skin diseases. No severe adverse events were observed in the trial.

On July 18, 2019, we received approval from the Israeli Medical Cannabis Agency to perform an efficacy study with OWC topical ointment on psoriatic patients. Currently, the study is planned to be conducted at the Kaplan Medical Center, an academic medical center in Israel.



Again it would be nice to give some sort of a hint of a timeline. But that's way too much to ask.

Unless we are told otherwise here you have the most current information pertaining to a possible revenue stream and ongoing studies. Both must be read with the proviso that for OWC, statements that contain words such as "intend" and "plan" should be taken with a grain of salt because for them these are forward looking statements, therefore you should make your decisions accordingly.